A somatostatin analogue decreases embryonic loss following superovulation in rats by normalizing insulin-like growth factor-I action in the uterus

This study was designed to determine whether the somatostatin analogue, octreotide, could prevent embryonic loss by normalizing increased uterine insulin-like growth factor-I (IGF-I) action related to hyperoestrogenaemia following superovulation, Superovulated immature and oestradiol-17 beta-treated adult rats were infused with 100 or 300 mu g/ml of octreotide respectively, or injected daily with 1 or 10 mu g of octreotide from day 1 to day 3 of pregnancy. On day 3, embryos were collected from the oviducts and uteri, Uterine luminal fluid was subjected to embryo culture, The amounts of uterine IGF-I and IGF binding proteins (IGFBP) were determined by radioimmunoassay and ligand binding assay respectively, Octreotide infusion normalized uterine IGF-I action following superovulatory and oestradiol-17 beta treatment, by reducing IGF-I concentrations and increasing IGFBP concentrations, Octreotide infusion increased the number of normal embryos by 2.7-fold and 1.7-fold in superovulated and oestradiol-17 beta-treated rats respectively, and reversed the detrimental effects of uterine luminal fluid on embryonic development caused by superovulatory and oestradiol-17 beta treatment, Daily injections with octreotide had similar but reduced effects in all parameters examined in both treatment groups, In conclusion, octreotide may reduce embryonic loss, at least in part, by normalizing IGF-I action following superovulation.